SAGE Journals Online
Advertisement
Sign In to gain access to subscriptions and/or personal tools.

 

Advanced Search

Journal Navigation

Journal Home

Subscriptions

Archive

Contact Us

Table of Contents

Advertisement

Sign In to gain access to subscriptions and/or personal tools.
Lupus
This Article
Right arrow Full Text (PDF)
Right arrow References
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Right arrow Citing Articles via Scopus
Google Scholar
Right arrow Articles by Cimaz, R
Right arrow Articles by Shoenfeld, Y
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Cimaz, R
Right arrow Articles by Shoenfeld, Y
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

Epilepsy as part of systemic lupus erythematosus and systemic antiphospholipid syndrome (Hughes syndrome)

R Cimaz

Départment de Pédiatrie, Hôpital Herriot, and Universitè Claude Bernard Lyon 1, Lyon, France, Roland.Cimaz{at}chu-lyon.fr

P L Meroni

Istituto Auxologico Italiano and Università di Milano, Italy

Y Shoenfeld

Department of Medicine ‘B’ and Center for Autoimmune Diseases, Sheba Medical Center, Tel-Hashomer, Israel and Research of Autoimmune Diseases, Tel-Aviv University, Israel

The antiphospholipid syndrome (APS) is defined by the presence of antiphospholipid antibodies (aPL), demonstrated by ELISAs for antibodies against phospholipids and associated phospholipid-binding cofactor proteins and/or a circulating lupus anticoagulant (LA) together with diverse systemic clinical manifestations such as thrombosis, and recurrent spontaneous abortions. According to the criteria set out in Sydney1 the only neurological manifestations that can be suitable as APS classification criteria are ischemic events (stroke and transient ischemic attacks). However, other neurological manifestations, including seizures in particular, have been repeatedly reported in APS patients.2

The present review will summarize recent research on the association of aPL, as well as other autoantibodies, with seizure disorders, with or without concomitant SLE.

Key Words: antiphospholipid • autoantibodies • autoimmune • epilepsy • seizures • systemic lupus erythematosus

Lupus, Vol. 15, No. 4, 191-197 (2006)
DOI: 10.1191/0961203306lu2272rr
Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?


This article has been cited by other articles:


Home page
 PNHome page
F. G Joseph and N. J Scolding
Neurolupus
Practical Neurology, February 1, 2010; 10(1): 4 - 15.
[Abstract] [Full Text] [PDF]

Home page
 LupusHome page
R. Cimaz and R. Guerrini
Epilepsy in lupus
Lupus, September 1, 2008; 17(9): 777 - 779.
[PDF]

Home page
 Rheumatology (Oxford)Home page
E. Descloux, I. Durieu, P. Cochat, D. Vital Durand, J. Ninet, N. Fabien, and R. Cimaz
Paediatric systemic lupus erythematosus: prognostic impact of antiphospholipid antibodies
Rheumatology, February 1, 2008; 47(2): 183 - 187.
[Abstract] [Full Text] [PDF]


Advertisement